123 related articles for article (PubMed ID: 9679739)
1. CA 125 elevations in patients with malignant lymphomas.
Fehm T; Beck E; Valerius T; Gramatzki M; Jäger W
Tumour Biol; 1998; 19(4):283-9. PubMed ID: 9679739
[TBL] [Abstract][Full Text] [Related]
2. Serum Ca 125 levels in children with acute leukemia and lymphoma.
Birgen D; Ertem U; Duru F; Sahin G; Yüksek N; Bozkurt C; Karacan CD; Aksoy C
Leuk Lymphoma; 2005 Aug; 46(8):1177-81. PubMed ID: 16085559
[TBL] [Abstract][Full Text] [Related]
3. CA 125 levels in patients with non-Hodgkin lymphoma and other hematologic malignancies.
Dilek I; Ayakta H; Demir C; Meral C; Ozturk M
Clin Lab Haematol; 2005 Feb; 27(1):51-5. PubMed ID: 15686508
[TBL] [Abstract][Full Text] [Related]
4. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
5. CA-125: a tumor marker in non-Hodgkin's lymphomas?
Pabst T; Ludwig C
J Clin Oncol; 1995 Jul; 13(7):1827-8. PubMed ID: 7602374
[No Abstract] [Full Text] [Related]
6. Haptoglobin-related protein as a serum marker in malignant lymphoma.
Epelbaum R; Shalitin C; Segal R; Valansi C; Arselan I; Faraggi D; Leviov M; Ben-Shahar M; Haim N
Pathol Oncol Res; 1998; 4(4):271-6. PubMed ID: 9887357
[TBL] [Abstract][Full Text] [Related]
7. Serum CA 125 as a prognostic factor in non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Stark P; Prokocimer M; Nativ HM; Kirgner I; Shaklai M
Leuk Lymphoma; 2003 Oct; 44(10):1733-8. PubMed ID: 14692526
[TBL] [Abstract][Full Text] [Related]
8. Serum L-selectin and P-selectin levels in lymphomas.
Haznedaroglu IC; Benekli M; Ozcebe O; Savaş MC; Güllü IH; Dündar SV; Kirazli S
Haematologia (Budap); 2000; 30(1):27-30. PubMed ID: 10841321
[TBL] [Abstract][Full Text] [Related]
9. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of the epithelial tumor marker CA-125 in non-Hodgkin's lymphoma.
Ozgüroglu M; Turna H; Demir G; Döventas A; Demirelli F; Mandel NM; Büyükünal E; Serdengeçti S; Berkarda B
Am J Clin Oncol; 1999 Dec; 22(6):615-8. PubMed ID: 10597748
[TBL] [Abstract][Full Text] [Related]
11. Serum immunoglobulins in leukaemia and malignant lymphoma.
Solanki RL; Anand VK; Arora HL
J Indian Med Assoc; 1990 Nov; 88(11):305-7. PubMed ID: 2086658
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of tumor markers CA 125 and CA 15.3 at diagnosis and during follow-up in non-Hodgkin's lymphoma: study of 200 patients.
Batlle M; Ribera JM; Oriol A; Pastor C; Mate JL; Fernández-Avilés F; Flores A; Millá F; Feliu E
Leuk Lymphoma; 2005 Oct; 46(10):1471-6. PubMed ID: 16194893
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of CA 125 in patients with non-Hodgkin's lymphoma.
Zacharos ID; Efstathiou SP; Petreli E; Georgiou G; Tsioulos DI; Mastorantonakis SE; Christakopoulou I; Roussou PP
Eur J Haematol; 2002 Oct; 69(4):221-6. PubMed ID: 12431241
[TBL] [Abstract][Full Text] [Related]
14. Serum ferritin in hematologic malignancies.
Matzner Y; Konijn AM; Hershko C
Am J Hematol; 1980; 9(1):13-22. PubMed ID: 7001894
[TBL] [Abstract][Full Text] [Related]
15. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
16. Serum ceruloplasmin levels in patients of leukaemias, Hodgkin's and non-Hodgkin's lymphomas.
Aggarwal AK; Sanwalka AB; Vadehra PL; Prabhakar BR
Indian J Pathol Microbiol; 1984 Oct; 27(4):347-52. PubMed ID: 6534868
[No Abstract] [Full Text] [Related]
17. Serum CA 125 levels in children with non-Hodgkin's lymphoma.
Kutluk T; Varan A; Erbaş B; Büyükpamukçu M
Pediatr Hematol Oncol; 1999; 16(4):311-9. PubMed ID: 10407867
[TBL] [Abstract][Full Text] [Related]
18. Serum CA 125 levels in patients with chronic lymphocytic leukemia.
Bairey O; Shaklai M
Clin Lab Haematol; 2005 Feb; 27(1):57-60. PubMed ID: 15686509
[TBL] [Abstract][Full Text] [Related]
19. [Quantitative measurement and clinical analysis of serum levels of immunosuppressive acidic protein (IAP) in hematopoietic malignancies].
Hamaguchi H; Karitani Y; Minami N; Tanaka I; Iwata Y; Shirakawa S
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1231-6. PubMed ID: 6732251
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
